A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug.

The present disclosure provides a method for lifting submucosal or mucosal tissues in a patient, comprising administrating to the tissues an effective amount of a thermosensitive gel composition comprising Poloxamer-407. A method for performing an endoscopic procedure, a method for submucosal or mucosal resectioning, a method for performing an endoscopic ultrasound procedure, and a method for performing a polyp removal are also provided.

Provided herein are methods for decreasing the toxicity of advanced ablative cancer therapies on neighboring organs. The methods herein provide spacing between single or multiple tumor cites and immediate healthy organs while maintaining or increasing patient quality of life. Such toxicity isolation can be performed by inserting a spacer around the one or more tumor cites, which can be performed concurrently with fiducial marker placement.

The invention provides a compound having the following structure:
T-DOTA-R,
wherein T is a carbohydrate polymer, R is a radioactive isotope, DOTA is a chelator of R, and T is covalently bond to DOTA. In one embodiment, the carbohydrate polymer is hyaluronic acid (HA). The compound or HA is used alone as a polymer or incorporated into a hydrogel for treating body cavity cancer, comprising administering an effective amount of the compound or hydrogel. The invention also provides a method for treating body cavity or soft tissue cancer comprising: introducing into the affected area a thermo reversible gel comprising the compound or HA, allowing the radioactive isotope to emit a therapeutic radiation to affected regions; and, after a predetermined time, optionally removing the gel from the body cavity with a cold rinse to liquefy the gel and allow it to exit the body cavity.

A radioactive thermogel suspension, including a thermogel and a plurality of insoluble radioactive isotope phosphate particles, such as yttrium phosphate, suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03 .Math.m and 10 .Math.m in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

A photocrosslinkable hydrogel may comprise a radioisotope-labeled photocrosslinkable compound or a pharmaceutically acceptable salt thereof, which may be used as a composition for radiotherapy, a composition for radiodiagnostic imaging and a composition for anticancer treatment. The hydrogel is excellent in staying in a local area requiring radiation treatment, so that it can be treated while minimizing damage to surrounding tissues. In addition, it can be used in combination with an anticancer agent and used as a pharmaceutical composition for anticancer treatment, so that cancer can be effectively treated. The hydrogel can be manufactured on site immediately and conveniently using a portable microfluidic system, thereby maximizing the radiation treatment effect.

Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

The invention relates generally to methods of using a thiol-Michael addition hydrogel for providing intracavitary brachytherapy and/or displacing tissue and organs. The thiol-Michael addition hydrogel may be used as a packing material and an attenuation material for intracavitary brachytherapy applications. The invention also relates generally to a brachytherapy applicator, which may be used in conjunction with the thiol-Michael addition hydrogel and methods thereof. The invention also relates to a positioning device system for providing intracavitary brachytherapy treatment and a kit thereof.

The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing the compositions, as well as methods of using the same.